A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated ... Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial R... Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval ...STOCK Quote
NASDAQ: AERI
$15.74USD
May 22, 4:00 PM ET
VOLUME
827,815
DAY LOW/HIGH
$15.72/$16.30
52 - WEEK LOW/HIGH
$10.80/$41.13
